Escape phenomenon with pravastatin during long-term treatment of patients with hyperlipidemia associated with diabetes mellitus

Current Therapeutic Research - Clinical and Experimental

Volumn 59, Issue 2, 1998, Pages 130-138

  Oi, Kazuteru ^a   Komori, Hiromi ^a  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

Author keywords

Dyslipidemia; Escape phenomenon; HMG CoA reductase inhibitor; Non insulin dependent diabetes mellitus; Pravastatin

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; INSULIN; PRAVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DISEASE ASSOCIATION; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERLIPIDEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0031929070     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(98)85009-1     Document Type: Article

References (23)

1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Result. I: Reduction in incidence of coronary heart disease. JAMA. 1984;251: 351-364.
2. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow up from the Framingham study. JAMA. 1987;257:2176-2180.
3. Santen RJ, Willis PW, Fajan SS. Atherosclerosis in diabetes mellitus. Ann Intern Med. 1972;130:833-843.
4. Briones ER, Mao SJT, Palmbo PJ, et al. Analysis of plasma lipids and apolipoproteins in insulin-dependent and non-insulin dependent diabetics. Metabolism. 1984;33:42-49.
5. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87;1781-1791.
6. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin: Improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524.
7. Yamamoto A, Goto Y, Yoshida S, et al. Study on clinical efficacy of CS-514 (pravastatin) in long-term treatment of hypercholesterolemia. J Clin Ther Med. 1990;4:409-437.
8. Nakaya N, Goto Y, Yoshida S, et al. Study on clinical efficacy of CS-514 (pravastatin) on hypercholesterolemia: Multiclinic open study. J Clin Ther Med. 1988;4:201-227.
9. Kanazawa T, Onodera K. Study on clinical efficacy and safety of Mevalotin® in patients with hyperlipidemia. Prog Med. 1993;13:2517-2523.
10. Okuda F, Mtuzaki M, Umemoto S, et al. Study on the effectiveness and safety of long-term administration of pravastatin for hypercholesterolemia. Prog Med. 1994;14:704-715.
11. Hamada C, Honda Y, Murakami Y, et al. Evaluation for the long-term efficacy and safety of pravastatin for the patients with hypercholesterolemia and diabetes mellitus using meta-analysis. Prog Med. 1996;16:1424-1430.
12. Illingworth DR, Sexton GJ. Hypercholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest. 1984;74:1972-1978.
13. Yamamoto A, Yokoyama S, Yamamura T. Escape phenomenon occurs by lowering cholesterol with a hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor in patients with familial hypercholesterolemia. Atherosclerosis. 1988;71:257-260.
14. Brown MS, Faust JR, Goldstein JL, et al. Induction of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human fibroblasts incubated with Compactin (ML-236B): A competitive inhibitor of the reductase. J Biol Chem. 1978;253:1121-1128.
15. Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta. 1979;575:266-276.
16. Chin DL, Lusky KL, Anderson RGW, et al. Appearance of crystalloid endoplasmic reticulum in compactin-resistant Chinese hamster cells with a 500-fold increase in 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Proc Natl Acad Sci USA. 1982;79: 1185-1189.
17. Naruse M, Yoshimoto T, Naruse K, et al. Effects of simvastatin on the escape phenomenon following pravastatin therapy in patients with hypercholesterolemia. J Jpn Atheroscler Soc. 1994;22:301-306.
18. Komori H, Oi K, Kajinuma H. Long-term (one year) study of once-daily administration of pravastatin (Mevalotin® 10 mg tablets) after breakfast for hyperlipidemia associated with diabetes. Prog Med. 1993;13:1886-1889.
19. Saito Y, Nakaya N, Matuzawa Y, et al. Clinical open study on hyperlipidemia at once daily dose of pravastatin (CS-514) for long-term treatment. J Clin Ther Med. 1991; 7:771-797.
20. Stone BG, Evans CD, Prigge WF, et al. Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects. J Lipid Res. 1989;30:1943-1952.
21. Duggan DE, Vickers S. Physiological disposition of HMG-CoA reductase inhibitors. Drug Metab Rev. 1990;22:333-362.
22. Pentikainen PJ, Saraheimo M, Schwartz JI, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol. 1992;32:136-140.
23. Nagata Y, Hidaka Y, Ishida F, et al. Effects of simvastatin (MK-733) on the regulation of cholesterol synthesis in hep G2 cells. Biochem Pharmacol. 1990;40:843-850.